<DOC>
	<DOC>NCT01287754</DOC>
	<brief_summary>This single arm, open-label study will assess the efficacy and safety of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. Patients will receive Tarceva at a dose of 150 mg daily orally until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Locally advanced or metastatic (stage III/IV) nonsmall cell lung cancer with EGFR mutations Measurable disease according to RECIST criteria ECOG performance status 02 Adequate haematological, renal and liver function Previous chemotherapy or therapy against EGFR for metastatic disease History of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis Symptomatic cerebral metastases Preexisting parenchymal lung disease such as pulmonary fibrosis Concomitant use of coumarins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>